Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1620 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Achillion Releases ACH-1625 Phase 1b Trial Data

Achillion Pharmaceuticals said that the subjects in the third cohort of HCV-infected patients received doses of 200mg twice-daily (randomised to 6 active drug, 3 placebo) for five days.

Ganeden Biotech Invention Receives USPTO Grant

Ganeden Biotech said that the new invention promises a better and easier solution to prevent lactose intolerance symptoms over the traditional practice of taking lactase enzyme alone before